Cargando…

Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia

Anti-angiogenic therapy is emerging as a valuable tool in the treatment of patients with cancer. As VEGF is a central target in anti-angiogenic therapy, its levels in the circulation might be relevant in selecting tumor types or patients likely to respond to this treatment. Additional VEGF has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusumanto, Yoka H., Meijer, Coby, Dam, Wendy, Mulder, Nanno H., Hospers, Geke A.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155238/
https://www.ncbi.nlm.nih.gov/pubmed/21901067
_version_ 1782210099234734080
author Kusumanto, Yoka H.
Meijer, Coby
Dam, Wendy
Mulder, Nanno H.
Hospers, Geke A.P.
author_facet Kusumanto, Yoka H.
Meijer, Coby
Dam, Wendy
Mulder, Nanno H.
Hospers, Geke A.P.
author_sort Kusumanto, Yoka H.
collection PubMed
description Anti-angiogenic therapy is emerging as a valuable tool in the treatment of patients with cancer. As VEGF is a central target in anti-angiogenic therapy, its levels in the circulation might be relevant in selecting tumor types or patients likely to respond to this treatment. Additional VEGF has been recognized as a key factor in the pathogenesis of diabetic retinopathy. Recently anti-angiogenic therapy has been advocated in this situation. We measured VEGF levels in whole blood in 42 patients with high grade (n = 26) and low grade (n = 16) end stage cancer, and in 28 healthy controls and 37 patients with diabetes related vascular disease. Only 2/26 patients in the group of high grade cancer had significantly elevated VEGF levels, 1/16 in the low grade group and 1/28 in the healthy control group. In contrast, in 10/37 diabetic patients the mean VEGF levels were significantly elevated compared to the other groups. The mean level in these diabetic patients was significantly elevated compared to the other groups. These data indicate the limitation of the use of circulating VEGF levels as a potential selection criterion for anti-angiogenic therapy in cancer patients and suggest further studies into its application in the management of diabetic complications.
format Online
Article
Text
id pubmed-3155238
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-31552382011-09-07 Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia Kusumanto, Yoka H. Meijer, Coby Dam, Wendy Mulder, Nanno H. Hospers, Geke A.P. Drug Target Insights Review Anti-angiogenic therapy is emerging as a valuable tool in the treatment of patients with cancer. As VEGF is a central target in anti-angiogenic therapy, its levels in the circulation might be relevant in selecting tumor types or patients likely to respond to this treatment. Additional VEGF has been recognized as a key factor in the pathogenesis of diabetic retinopathy. Recently anti-angiogenic therapy has been advocated in this situation. We measured VEGF levels in whole blood in 42 patients with high grade (n = 26) and low grade (n = 16) end stage cancer, and in 28 healthy controls and 37 patients with diabetes related vascular disease. Only 2/26 patients in the group of high grade cancer had significantly elevated VEGF levels, 1/16 in the low grade group and 1/28 in the healthy control group. In contrast, in 10/37 diabetic patients the mean VEGF levels were significantly elevated compared to the other groups. The mean level in these diabetic patients was significantly elevated compared to the other groups. These data indicate the limitation of the use of circulating VEGF levels as a potential selection criterion for anti-angiogenic therapy in cancer patients and suggest further studies into its application in the management of diabetic complications. Libertas Academica 2007-05-18 /pmc/articles/PMC3155238/ /pubmed/21901067 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Kusumanto, Yoka H.
Meijer, Coby
Dam, Wendy
Mulder, Nanno H.
Hospers, Geke A.P.
Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
title Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
title_full Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
title_fullStr Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
title_full_unstemmed Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
title_short Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
title_sort circulating vascular endothelial growth factor (vegf) levels in advanced stage cancer patients compared to normal controls and diabetes mellitus patients with critical ischemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155238/
https://www.ncbi.nlm.nih.gov/pubmed/21901067
work_keys_str_mv AT kusumantoyokah circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia
AT meijercoby circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia
AT damwendy circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia
AT muldernannoh circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia
AT hospersgekeap circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia